Advancing a Focused Oncology Pipeline

A disciplined development strategy led by BT-1501 in advanced colorectal cancer, with expansion across the TASIN platform.

A Lead Program with Platform Potential

Barricade’s development strategy is centered on BT-1501, an investigational oral therapy targeting APC-mutant colorectal cancer.

The Company is advancing BT-1501 in patients with advanced Stage IV CRC who have progressed following standard-of-care therapy, while leveraging its TASIN platform to explore additional oncology and neurology indications.

Development progress includes completed GLP toxicology, GMP manufacturing activities, and constructive Pre-IND engagement with the U.S. FDA.

BT-1501 represents Barricade’s lead clinical asset and the foundation for broader platform expansion.

Expanding the TASIN Platform

Beyond advanced CRC, Barricade is evaluating TASIN-based compounds across additional oncology and neurology indications where APC-driven or related genetic vulnerabilities may be present.

Current expansion efforts include:

Neuroblastoma / Lymphoma (Oncology)

• Candidate selection underway

• IND and Phase 1 development planning

Multiple Sclerosis (Neurology)

• Preclinical program development

• IND-enabling studies anticipated

Familial Adenomatous Polyposis (FAP)

• Prevention-focused development strategy

• Phase 2 study planning contingent on clinical progress

This approach balances scientific rigor with disciplined capital deployment.

A Structured and Capital-Efficient Pathway

Barricade’s development model emphasizes:

  • Focused clinical prioritization

  • Milestone-driven advancement

  • Strategic partnership flexibility

  • Expansion into additional high-value indications

This approach is designed to balance scientific rigor with disciplined capital deployment.

Building a Multi-Indication Platform

Advancing BT-1501 through clinical development while expanding the TASIN platform across oncology and neurology.